AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38526047 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-752 750 mg TID
Number of subjects: 0
Study 38526047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38526054 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1647 vaccine (three-dose series)
Number of subjects: 0
Study 38526122 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Muscle Reinnervation (TMR)
Number of subjects: 0
Study 38526122 — intervention group
Group type: COMPARATOR
Intervention: Other surgical techniques for managing postamputation pain
Number of subjects: 0
Study 38526296 — intervention group
Group type: EXPERIMENTAL
Intervention: Droplet digital PCR (DDPCR) assay
Number of subjects: 107
Study 38526461 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 621
Study 38526461 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific Oral Migraine Preventives (OMPMs)
Number of subjects: 621
Study 38526549 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Family Integrated Care (FICare) including information booklet, workbook, classes, and a father peer-support group
Number of subjects: 40
Study 38526549 — intervention group
Group type: COMPARATOR
Intervention: Standard Family Integrated Care (FICare) practices
Number of subjects: 40
Study 38526549 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Family Integrated Care (FICare)
Number of subjects: 40
Study 38526550 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 54
Study 38526550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine
Number of subjects: 54
Study 38526550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 38526612 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin, a muscarinic receptor antagonist, dosage and duration not specified
Number of subjects: 0
Study 38526612 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38526642 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey measuring HIV-related shame (13-item measure, Range: 0-52)
Number of subjects: 103
Study 38526642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable regression analysis
Number of subjects: 103
Study 38526642 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative in-depth interviews
Number of subjects: 103
Study 38526764 — intervention group
Group type: EXPERIMENTAL
Intervention: NSEIT (3 months of neck-specific rehabilitation with internet support + 4 physiotherapy visits)
Number of subjects: 140
Study 38526764 — intervention group
Group type: COMPARATOR
Intervention: NSE (same exercises performed twice a week at a physiotherapy clinic for 3 months)
Number of subjects: 140
Study 38526832 — intervention group
Group type: EXPERIMENTAL
Intervention: SL (staging strategy)
Number of subjects: 0
Study 38526832 — intervention group
Group type: COMPARATOR
Intervention: Routine staging (not specified)
Number of subjects: 0
Study 38526910 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation EGFR-TKIs in T790M-positive patients (Group A)
Number of subjects: 40
Study 38526910 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation EGFR-TKIs in T790M-negative patients (Group B)
Number of subjects: 40
Study 38526910 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group C)
Number of subjects: 40
Study 38526971 — intervention group
Group type: EXPERIMENTAL
Intervention: HUK
Number of subjects: 80
Study 38526971 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 38527058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth Open Swallowing Maneuver (MOSM)
Number of subjects: 50
Study 38527058 — intervention group
Group type: COMPARATOR
Intervention: Tongue-Hold Maneuver (THM)
Number of subjects: 50
Study 38527058 — intervention group
Group type: COMPARATOR
Intervention: Mendelsohn Maneuver (MM)
Number of subjects: 50
Study 38527058 — intervention group
Group type: COMPARATOR
Intervention: Dry Swallowing (DS)
Number of subjects: 50
Study 38527130 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoarterial extracorporeal membrane oxygenation (VA-ECMO)
Number of subjects: 0
Study 38527130 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation
Number of subjects: 0
Study 38527149 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (n=58)
Number of subjects: 120
Study 38527149 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access (n=58)
Number of subjects: 120
Study 38527482 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 8625
Study 38527482 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 8625
Study 38527482 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaths following postoperative complications
Number of subjects: 8625
Study 38527482 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating room safety for anaesthesia and surgery
Number of subjects: 8625
Study 38527588 — intervention group
Group type: EXPERIMENTAL
Intervention: New rejection classification using 6 rejection classifiers
Number of subjects: 3230
Study 38527588 — intervention group
Group type: EXPERIMENTAL
Intervention: TCMR
Number of subjects: 3230
Study 38527588 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMR
Number of subjects: 3230
Study 38527588 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft survival and left ventricular ejection fraction
Number of subjects: 3230
Study 38527605 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 3 'more accurate' treatment success definitions (International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form score ≤5, Urogenital Distress Inventory-6 score ≤33.3, no/mild stress urinary incontinence response on Urogenital Distress Inventory-6 question 3)
Number of subjects: 51
Study 38527605 — intervention group
Group type: COMPARATOR
Intervention: Composite definition of success (no reported urine leakage, negative cough stress test result, and no retreatment)
Number of subjects: 51
Study 38527849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pascolizumab 2.5 mg/kg
Number of subjects: 29
Study 38527849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pascolizumab 10 mg/kg
Number of subjects: 29
Study 38527849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 38527849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pascolizumab (both doses)
Number of subjects: 29
Study 38528059 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost magnet tracking device
Number of subjects: 10
Study 38528164 — intervention group
Group type: EXPERIMENTAL
Intervention: novel radiolabelled somatostatin receptor antagonist
Number of subjects: 0
Study 38528239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic whole-body imaging (D-WB)
Number of subjects: 10
Study 38528257 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 1609
Study 38528257 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 1609
Study 38528257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1609
Study 38528445 — intervention group
Group type: EXPERIMENTAL
Intervention: epcoritamab plus lenalidomide
Number of subjects: 284
Study 38528445 — intervention group
Group type: COMPARATOR
Intervention: investigator choice standard therapy (ICT)
Number of subjects: 284
Study 38528456 — intervention group
Group type: EXPERIMENTAL
Intervention: Online adaptive radiotherapy (oART) with daily automated treatment re-planning
Number of subjects: 205
Study 38528456 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy
Number of subjects: 205
Study 38528456 — intervention group
Group type: EXPERIMENTAL
Intervention: Online adaptive radiotherapy (oART)
Number of subjects: 205
Study 38528476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 445
Study 38528476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (various doses)
Number of subjects: 445
Study 38528476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (dose adjustments)
Number of subjects: 445
Study 38528476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Number of subjects: 445
Study 38528476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan with concomitant triptans
Number of subjects: 445
Study 38528477 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Room (ER) admission
Number of subjects: 2291
Study 38528477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Care Unit (ICU) admission
Number of subjects: 2291
Study 38528477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward (ADM) admission
Number of subjects: 2291
Study 38528477 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 2291
Study 38528570 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive-TeleHarm Reduction (C-THR) intervention
Number of subjects: 350
Study 38528570 — intervention group
Group type: COMPARATOR
Intervention: non-SSP clinic referral and patient navigation
Number of subjects: 350
Study 38528570 — intervention group
Group type: EXPERIMENTAL
Intervention: C-THR intervention
Number of subjects: 350
Study 38528580 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen to HDL-cholesterol ratio (FHR) in the top quartile
Number of subjects: 13221
Study 38528580 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen to HDL-cholesterol ratio (FHR)
Number of subjects: 13221
Study 38529197 — intervention group
Group type: EXPERIMENTAL
Intervention: Removing Environmental Barriers to Independent Living (REBIL) intervention (total five visits)
Number of subjects: 0
Study 38529197 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (offered REBIL after 6-month follow-up)
Number of subjects: 0
Study 38529215 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of chronic illness management
Number of subjects: 1397
Study 38529234 — intervention group
Group type: EXPERIMENTAL
Intervention: traditional RFA (t-RFA)
Number of subjects: 143
Study 38529234 — intervention group
Group type: EXPERIMENTAL
Intervention: cooled RFA (c-RFA)
Number of subjects: 143
Study 38529234 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 143
Study 38529324 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 60
Study 38529324 — intervention group
Group type: COMPARATOR
Intervention: Transmuscular Quadratus Lumborum Block (TQLB)
Number of subjects: 60
Study 38529519 — intervention group
Group type: EXPERIMENTAL
Intervention: IV SafeLock
Number of subjects: 20
Study 38529674 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg QD
Number of subjects: 203
Study 38529674 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 12 mg QD
Number of subjects: 203
Study 38529674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 38529685 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg ReCOV
Number of subjects: 0
Study 38529685 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg ReCOV
Number of subjects: 0
Study 38529685 — intervention group
Group type: COMPARATOR
Intervention: COVILO® (inactivated vaccine)
Number of subjects: 0
Study 38529685 — intervention group
Group type: COMPARATOR
Intervention: 30 μg BNT162b2 (COMIRNATY®)
Number of subjects: 0
Study 38529685 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg ReCOV (pilot batch, ReCOV HA)
Number of subjects: 0
Study 38529685 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg ReCOV (commercial batch, ReCOV TC)
Number of subjects: 0
Study 38530061 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 38530160 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LTZ) 15 mg daily
Number of subjects: 21
Study 38530160 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LTZ)
Number of subjects: 21
Study 38530213 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy following peri-implantitis treatment (SPIT)
Number of subjects: 159
Study 38530213 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive information provided prior to peri-implantitis treatment
Number of subjects: 159
Study 38530213 — intervention group
Group type: COMPARATOR
Intervention: Smoking and grade C periodontitis
Number of subjects: 159
Study 38530213 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 159
Study 38530261 — intervention group
Group type: EXPERIMENTAL
Intervention: Early repair strategy (surgery before NICU discharge)
Number of subjects: 338
Study 38530261 — intervention group
Group type: COMPARATOR
Intervention: Late repair strategy (surgery after NICU discharge, >55 weeks' postmenstrual age)
Number of subjects: 338
Study 38530261 — intervention group
Group type: EXPERIMENTAL
Intervention: Early repair strategy
Number of subjects: 338
Study 38530261 — intervention group
Group type: COMPARATOR
Intervention: Late repair strategy
Number of subjects: 338
Study 38530345 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status assessment through laboratory testing and questionnaire survey
Number of subjects: 414
Study 38530345 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 subjects)
Number of subjects: 414
Study 38530345 — intervention group
Group type: EXPERIMENTAL
Intervention: Case group (22 subjects)
Number of subjects: 414
Study 38530346 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-facilitated screening and brief intervention (cSBI) system (CRAFFT Interactive System)
Number of subjects: 1300
Study 38530346 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1300
Study 38530349 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE support services
Number of subjects: 0
Study 38530349 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 38530349 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE clinical pathway
Number of subjects: 0
Study 38530474 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride-containing dentifrice twice daily (test group, n=66)
Number of subjects: 197
Study 38530474 — intervention group
Group type: COMPARATOR
Intervention: 5.0% calcium sodium phosphosilicate-containing dentifrice twice daily (positive control group, n=64)
Number of subjects: 197
Study 38530474 — intervention group
Group type: COMPARATOR
Intervention: 1150 ppm NaF dentifrice twice daily (negative control group, n=67)
Number of subjects: 197
Study 38530490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 276
Study 38530565 — intervention group
Group type: EXPERIMENTAL
Intervention: epacadostat 100 mg orally twice-daily, pembrolizumab 200 mg intravenously every 3 weeks for ≤ 35 cycles, and 4 cycles of chemotherapy (cisplatin plus pemetrexed, non-squamous)
Number of subjects: 19
Study 38530565 — intervention group
Group type: EXPERIMENTAL
Intervention: epacadostat 100 mg orally twice-daily, pembrolizumab 200 mg intravenously every 3 weeks for ≤ 35 cycles, and 4 cycles of chemotherapy (carboplatin plus pemetrexed, non-squamous)
Number of subjects: 19
Study 38530565 — intervention group
Group type: EXPERIMENTAL
Intervention: epacadostat 100 mg orally twice-daily, pembrolizumab 200 mg intravenously every 3 weeks for ≤ 35 cycles, and 4 cycles of chemotherapy (carboplatin plus paclitaxel, squamous or non-squamous)
Number of subjects: 19
Study 38530565 — intervention group
Group type: EXPERIMENTAL
Intervention: epacadostat plus pembrolizumab and chemotherapy
Number of subjects: 19
Study 38530569 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) followed by brachytherapy
Number of subjects: 86
Study 38530569 — intervention group
Group type: EXPERIMENTAL
Intervention: Restaging tumor size (rTS) > 2.55 cm
Number of subjects: 86
Study 38530569 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial tumor volume (iTV) > 55.99 cc
Number of subjects: 86
Study 38530569 — intervention group
Group type: EXPERIMENTAL
Intervention: Restaging tumor volume (rTV) > 6.25 cc
Number of subjects: 86
Study 38530569 — intervention group
Group type: EXPERIMENTAL
Intervention: Downstaging
Number of subjects: 86
Study 38530572 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with uncontrolled hypertension
Number of subjects: 523
Study 38530572 — intervention group
Group type: COMPARATOR
Intervention: Men with uncontrolled hypertension
Number of subjects: 523
Study 38530609 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy
Number of subjects: 37
Study 38530609 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal parathyroidectomy
Number of subjects: 37
Study 38531002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily for 52 weeks
Number of subjects: 129
Study 38531002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 38531002 — intervention group
Group type: COMPARATOR
Intervention: Pazopanib vs Placebo
Number of subjects: 129
Study 38531058 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 0
Study 38531058 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 38531149 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOT training (experimental group)
Number of subjects: 60
Study 38531149 — intervention group
Group type: COMPARATOR
Intervention: Non-specific cognitive training (CON) (control group)
Number of subjects: 60
Study 38531325 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Pi*ZZ phenotype
Number of subjects: 123
Study 38531325 — intervention group
Group type: EXPERIMENTAL
Intervention: BODE index
Number of subjects: 123
Study 38531325 — intervention group
Group type: EXPERIMENTAL
Intervention: BODEx
Number of subjects: 123
Study 38531325 — intervention group
Group type: EXPERIMENTAL
Intervention: DLCO
Number of subjects: 123
Study 38531362 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional optoacoustic imaging in pediatric patients with spinal muscular atrophy
Number of subjects: 20
Study 38531362 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional optoacoustic imaging in patients who received disease-modifying therapy
Number of subjects: 20
Study 38531362 — intervention group
Group type: COMPARATOR
Intervention: Standard motor function tests
Number of subjects: 20
Study 38531539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 144
Study 38531539 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 144
Study 38531539 — intervention group
Group type: EXPERIMENTAL
Intervention: WB-DWI/MRI
Number of subjects: 144
Study 38531570 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision dosing of infliximab with a clinical decision support tool (RoadMAB) targeting specific trough concentrations and pharmacodynamic targets.
Number of subjects: 180
Study 38531570 — intervention group
Group type: COMPARATOR
Intervention: Conventional care dosing of infliximab with a modified starting dose (5 or 7.5 mg/kg based on pretreatment serum albumin) aiming for maintenance trough concentrations of 5-10 µg/mL.
Number of subjects: 180
Study 38531584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve cryoablation
Number of subjects: 50
Study 38531584 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia
Number of subjects: 50
Study 38531585 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Pump Therapy (IPT)
Number of subjects: 2068
Study 38531585 — intervention group
Group type: COMPARATOR
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 2068
Study 38531585 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Pump Therapy (IPT) with BGM
Number of subjects: 2068
Study 38531585 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Pump Therapy (IPT) with CGM
Number of subjects: 2068
Study 38531585 — intervention group
Group type: COMPARATOR
Intervention: Continuous Glucose Monitoring (isCGM vs rtCGM)
Number of subjects: 2068
Study 38531621 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab every 4 weeks (Q4W)
Number of subjects: 493
Study 38531621 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab every 8 weeks (Q8W)
Number of subjects: 493
Study 38531621 — intervention group
Group type: COMPARATOR
Intervention: guselkumab
Number of subjects: 493
Study 38531658 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice, e-cigarette starter kit and referral to stop smoking services
Number of subjects: 972
Study 38531658 — intervention group
Group type: COMPARATOR
Intervention: Written information on stop smoking services
Number of subjects: 972
Study 38531756 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolisation (PAE)
Number of subjects: 103
Study 38531756 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 103
Study 38531812 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood (WB) resuscitation
Number of subjects: 21
Study 38531939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose computed tomography (ULD-CT)
Number of subjects: 50
Study 38531939 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 50
Study 38531939 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery or stereotactic body radiation therapy (SBRT)
Number of subjects: 50
Study 38531939 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 50
Study 38532144 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (MEP) for 11 months, starting 1-month post-bariatric surgery, in addition to standard medical care.
Number of subjects: 84
Study 38532144 — intervention group
Group type: COMPARATOR
Intervention: Control group received medical care recommendations only.
Number of subjects: 84
Study 38532181 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral PVI
Number of subjects: 50
Study 38532181 — intervention group
Group type: COMPARATOR
Intervention: Ostial PVI
Number of subjects: 50
Study 38532181 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing PVI gap numbers
Number of subjects: 50
Study 38532181 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-PV induction
Number of subjects: 50
Study 38532181 — intervention group
Group type: COMPARATOR
Intervention: Internal PV induction
Number of subjects: 50